Berry softball coach Darrell Thomas leads team into North Regional next week while undergoing chemotherapy treatments.

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Heidi Shupe has a myriad of medals proudly displayed in her home. But 20 years ago, her life looked a lot different.

Q1 2025 Management View CEO Chad Robins highlighted a strong start to the year, with MRD revenue increasing 34% year-over-year, driven by clinical volumes, ASP improvements, and pharma sequencing. The ...

Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March ...

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company ...

follicular lymphoma marginal zone lymphoma mantle cell lymphoma anemia that’s caused by myelodysplastic syndrome multiple myeloma Revlimid belongs to a class of drugs called thalidomide analogues.

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.